The antitrust analysis of product hopping is nuanced. The conduct, which consists of a drug company’s reformulation of its product and encouragement of doctors to switch prescriptions to the reformulated product, sits at the intersection of antitrust law, patent law, the Hatch-Waxman Act, and state substitution laws, and involves uniquely complicated markets with different buyers … Continue reading Prof. Carrier writes article on product hopping…
Category: News
Prof. Carrier quoted in NY Times
Professor Carrier was quoted in the N.Y. Times on Allergan’s strategy of transferring patents to a Native American tribe to avoid review at the Patent Office.
Ellen P. Goodman quoted in Atlantic on Smart Homes
https://www.theatlantic.com/family/archive/2018/12/smart-home-devices-data-privacy/578425/
Biosimilars: The New Pharmaceutical Frontier
Michael Carrier will speak on the ABA Section of Antitrust Law, Federal Civil Enforcement Committee Program on Dec. 10, 2018
Despite dominance in range of industries,
Amazon could be favorable acquirer of 21st Century Fox’s regional sports networks from an antitrust perspective, according to @profmikecarrier. https://news.bloomberglaw.com/mergers-and-antitrust/amazons-sports-tv-bid-is-easy-legal-case-then-theres-trump